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ABSTRACT
The landscape for patients with Barrett’s
oesophagus (BE) has changed significantly in the
last decade. Research and new guidelines have
helped gastroenterologists to better identify those
patients with BE who are particularly at risk of
developing oesophageal adenocarcinoma. In
parallel, developments in endoscopic image
enhancement technology and optical biopsy
techniques have improved our ability to detect
high-risk lesions. Once these lesions have been
identified, the improvements in minimally invasive
endoscopic therapies has meant that these
patients can potentially be cured of early cancer
and high-risk dysplastic lesions without the need
for surgery, which still has a significant morbidity
and mortality. The importance of reaching an
accurate diagnosis of BE remains of paramount
importance. More work is needed, however. The
vast majority of those undergoing surveillance for
their BE do not progress towards cancer and thus
undergo a regular invasive procedure, which may
impact on their psychological and physical well-
being while incurring significant cost to the
health service. New work that explores cheaper
endoscopic or non-invasive ways to identify the
at-risk individual provides exciting avenues for
research. In future, the diagnosis and monitoring
of patients with BE could move away from
hospitals and into primary care.
INTRODUCTION
The incidence of oesophageal adenocar-
cinoma has been rising over the past
40 years such that oesophageal cancer is
now the fourth most common cause of
cancer death in men in the UK. Barrett’s
oesophagus (BE) is the only identifiable
premalignant condition for oesophageal
adenocarcinoma. Interventions are
focused on reducing the risk of progres-
sing from BE to oesophageal adenocar-
cinoma. A series of important changes
have come about in the past few years in
the field of BE. These include clear
national guidelines on the management
of patients with BE. These help guide
gastroenterologists to make evidence-
based choices to support, monitor and
treat their patients in ways that were not
previously available. A few timeless con-
cepts remain key: getting the correct
diagnosis, stratifying risk and only inter-
vening when it is safe and cost-effective
to do so.
MAKING THE DIAGNOSIS
The first step is accurate diagnosis. BE is
a metaplasia of the distal oesophagus
where the normal squamous lining
changes to a columnar one. This is
believed to occur in response to gastro-
oesophageal reflux. Three distinct types
of cells are involved: gastric fundic type,
cardiac type and the most important type
—intestinal metaplasia (IM), which is
characterised by the presence of goblet
cells.1 There has been a long-standing
debate about the relative cancer risks of
these different tissue types as well as the
importance of the length of the Barrett’s
segment. Additionally, there is likely to
be a contribution from lifestyle, inherited
factors and molecular alterations. The
picture is therefore not entirely
straightforward.
RECOGNISING WHAT IS NOT BE
Endoscopic diagnosis
The definition of BE relies on a combin-
ation of endoscopic findings and histo-
pathological analysis. BE should only be
diagnosed when there is a clearly visible
change from squamous to columnar epi-
thelium endoscopically in the distal
oesophagus, starting at the gastro-
oesophageal junction (GOJ).2
There are two catches to be aware of.
The first is that many endoscopists over-
diagnose BE. It is important not to label
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people with this diagnosis if they do not have an
increased risk of cancer. Endoscopists should avoid
diagnosing an irregular squamocolumnar junction
(z line), with columnar-lined tongues of only a few
millimetres as BE, or even worse, taking biopsies from
the gastric cardia, demonstrating IM and labelling it as
BE when there is no visible columnar epithelium at
all. It is well known that up to 18% of normal people
will have this finding and that their risk of developing
cancer is not increased.3–5 Furthermore, an irregular z
line is more common in patients with reflux disease.6
The second catch is noticing an area of columnar
metaplasia in the proximal oesophagus and incorrectly
labelling this as BE. This is actually a cervical inlet
patch and is a developmental abnormality.
Traditionally, it is thought to occur in around 2% of
the population, but with narrow band imaging (NBI)
and careful examination, it can be found in more than
10%.7 Inlet patches very rarely have IM and even
more rarely develop cancer. They may cause globus
symptoms and there is a literature developing around
ablation to relieve symptoms.8 9 They should not
however be confused with BE nor be treated as such.
IM or not?
The latest BSG guidelines stipulate that the presence
of IM, although highly corroborative, is not specific
for a diagnosis of BE as it can be confused with IM of
the gastric cardia. There is evidence to suggest that
IM is the most biologically unstable tissue type and
therefore has the greatest risk of developing cancer.
The population-based Northern Ireland BE register
found that the annual incidence of high-grade dyspla-
sia (HGD) and cancer in patients with IM was 0.38%
compared with 0.07% in those without.10 There is
also evidence that the likelihood of detecting IM is
low when insufficient biopsies are taken. Even if eight
biopsies are taken from the BE segment, only
two-thirds of patients with IM will actually be
detected.11
WHO SHOULD WE MONITOR?
Screening
An obvious question is whether we should screen for
BE? The population prevalence of BE is around 1%–
2%.12 13 Established risk factors include older age,
male gender and a history of reflux symptoms.14 15
Metabolic obesity with an enlarged waist-to-hip ratio
is also important. There may be familial clustering of
BE so a positive family history may be associated with
increased cancer risk and genetic factors are impli-
cated.16 The National Institute for Health and Care
Excellence (NICE) guidelines on management of dys-
pepsia published in 2014 recommend that endoscopy
should be considered if a patient with gastro-
oesophageal reflux disease has these risk factors or
others such as long duration of symptoms, increased
frequency of symptoms, previous oesophagitis,
previous hiatus hernia, oesophageal stricture or
oesophageal ulcers.17 It should not, however, be
offered routinely to the general population.
Surveillance and cancer risk
NICE recommends considering surveillance to check
for progression to cancer for people who already have
a diagnosis of BE confirmed by endoscopy and histo-
pathology, having taken into account the patient’s pre-
ferences and risk factors. An important caveat is that
the harms of endoscopic surveillance may outweigh
the benefits particularly in patients at low risk of pro-
gression to cancer, such as those with stable non-
dysplastic BE.17 The annual risk for developing cancer
has been shown in large population studies to be as
low as 0.16%, increasing to 0.38% when only patients
with IM were analysed in one study10 and 0.12% in
another.18
A meta-analysis of 57 studies calculated a similar
annual cancer incidence of 0.33%.19 The actual risk:
benefit ratio for endoscopic surveillance has not been
adequately proven and the results of the BOSS rando-
mised controlled trial (RCT) will shed light on this,
although they will not be available for some years.20
Clearly, targeting those at highest risk will lead to a
better profile for surveillance. A less invasive surveil-
lance approach would also be a significant advantage
(see below). It is also worth remembering that patients
with non-dysplastic BE are 10 times more likely to die
from an unrelated cause rather than cancer.19 In view
of this, the BSG guidelines make it clear that patients
with a short segment of BE and who have had two
consecutive endoscopies demonstrating gastric meta-
plasia only should be discharged from surveillance as
their cancer risk is 1:1400 years of follow-up.
Only a few years ago, a patient who was not fit for
oesophagectomy would no longer be offered surveil-
lance. With the advent of highly successful endoscopic
treatment for dysplasia,21–23 this is no longer appro-
priate. Even those with more advanced disease can
now be offered chemo-radiotherapy such that high-
risk patients should continue to be surveyed if they
are fit enough to withstand these treatments.24
COMMUNICATION
In a typical busy endoscopic environment, it is all too
easy for the doctor to confirm the presence of
low-risk BE, tell the patient not to worry and leave it
at that. The Internet has encouraged people to seek
out their own information and when that given by the
hospital is inadequate, many do so. A cursory online
search is likely to suggest an unreasonably high cancer
risk. This leads to unnecessary anxiety for patients. In
these days of instant communication, doctors should,
at the very least, point their patients to high-quality
information sources. For example, the Heartburn
Cancer UK website hosts some useful free, well-
written, patient leaflets.25
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Doctors should be clear with patients about the
relative risks and benefits of surveillance. High-risk
individuals should be made aware of the risks of not
being surveyed and those at lower risk should be
aware that the risks of the procedure may outweigh
the benefits both physically and psychologically.26 27
It is well known that many patients do not attend
their surveillance procedures, so robust support
mechanisms should be put in place to support these
programmes. This may take the form of dedicated
support from clinical nurse specialists.
ENDOSCOPIC TECHNIQUES
Endoscopic assessment
To be certain whether there is a columnar-lined
oesophagus the GOJ must be clearly defined. This is
best done by partially deflating the oesophagus. The
gastric folds then become clear. This defines
the GOJ.28 29 Another useful landmark is visualising
the distal end of the palisade vessels, which are only
visible in oesophagus.30 Not surprisingly there can be
some disagreement between these two landmarks.
Standardised description of BE
Standardised reporting is important. The Prague
C&M classification for BE is based on explicit,
consensus-driven criteria and is well validated.31 32 It
describes the length of circumferential and maximum
extent of the endoscopically visualised BE segment
and should be used routinely. In addition, when
visible lesions are noted, they should be recorded
using the Paris classification.33 This is a useful, repro-
ducible, shorthand tool for describing the Barrett’s,
which helps dialogue between clinicians and patients.
Advanced endoscopic imaging
There is no doubt in the minds of experts that the
higher the quality of the endoscope, the more likely
the doctor is to detect subtle abnormalities within the
BE.34 High-resolution endoscopy now offers 0.85 to
1.2 megapixel resolution and it continues to improve
with both enhancements to white light endoscopy and
complementary techniques.
Use of chromoendoscopy
Many units also have the option for either conven-
tional or virtual chromoendoscopy. All work to
enhance visualisation of mucosal or vascular patterns.
Methylene blue does not add much,35 nor does
indigo carmine.36 Acetic acid (figure 1) may improve
sensitivity of dysplasia detection, but the evidence is
conflicting.37 38 The advent of virtual chromoendo-
scopy, which is activated by a toggle button on the
endoscope, has reduced the need for these dyes
through the manipulation of the white light images.
NBI (Olympus) illuminates with only two narrow
bands of light—blue (415 nm) and green (540 nm).
These colours only penetrate the superficial layers of
the mucosa. These produce an image that enhances
superficial mucosa and vascular structures. NBI has a
high sensitivity for detecting dysplasia. A recent study
has suggested that targeting areas of abnormalities
seen under NBI might be able to replace random
biopsies,39 although interobserver agreement is only
moderate.40
i-Scan (Pentax) utilises postprocessing technology to
offer several modes of image enhancement. i-Scan
improves detection of BE compared with standard
white light endoscopy, particularly when combined
with zoom imaging (figure 1).38
Fuji Intelligent Colour Enhancement or optical
band imaging limits the wavelength range of the light.
A proprietary algorithm makes it possible to select
from a large number of wavelength combinations to
alter the display of the mucosa depending on location
and aim. The postprocessing technology converts
images into individual wavelengths and reconstructs
them to generate real-time enhanced images.
Figure 1 Endoscopic images of Barrett’s mucosa (×136 zoom
using Pentax iScan surface enhancement imaging). (A) Normal.
(B) Dysplastic area after application of 3% acetic acid (AcA),
showing typical ‘loss of aceto-whitening’ and distortion of
mucosal pattern. This usually becomes clear within 30–60 s of
AcA application.
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Perhaps the most important finding is that these
enhanced imaging techniques may be no better than
looking for longer using high-quality white light
imaging.36 Nonetheless, most expert endoscopists
agree that these extra imaging modalities enhance
their diagnostic toolkit.
Take enough biopsies
On a busy endoscopy list, it is difficult to make the
time to take random biopsies in line with the gold
standard of four quadrant biopsies every 2 cm (The
Seattle protocol).27 For this reason, it is increasingly
common to have dedicated Barrett surveillance lists
where fewer patients are booked and each procedure
is allotted two points rather than the standard one
point. Particularly if there is a long segment of BE, it
is often wiser to sedate the patient so that they can
tolerate the extensive biopsy protocol.
But can we avoid biopsies altogether?
More accurate visualisation of abnormalities followed
by targeted biopsies has been the aim of enhanced
endoscopic techniques for years. Even better, a non-
invasive way to detect disease would be a big step
forward.
A series of technologies have tried to address these
issues. Confocal laser endomicroscopy (CLE) is per-
formed with a probe that is passed through the
working channel of an endoscope (pCLE, Cellvizio;
Mauna Kea Technologies, Paris, France). Focused
infrared light is reflected through a pinhole and gener-
ates grey-scale images once the tissue is made to fluor-
esce with topical or intravenous agents. High
resolution of microstructures can be visualised in
similar detail to histological sections. The probe pro-
duces images with a resolution of less than 10 m. This
makes it possible to see individual cells as well as
tissue architecture. Unfortunately, in an RCT, it was
not good enough to completely replace biopsies in
BE.41
Autoflouresence (AF) detects fluorophores (sub-
stances that emit fluorescent light after exposure to
short, blue light wavelengths). The AF pattern changes
when tissue becomes neoplastic due to altered meta-
bolic activity and haemoglobin content together with a
breakdown of collagen fibre cross-links. This results in
a shift towards the red spectrum when such tissue is
excited with blue light. AF has been integrated with
high definition white light endoscopy (HD-WLE) and
NBI as part of the ‘endoscopic trimodal imaging’
system, although supporting evidence only exists cur-
rently for detection of early dysplasia in BE and polyp
differentiation in the colon.42 43
Optical coherence tomography uses reflected light
in a manner similar to acoustic ultrasound to generate
high-resolution three-dimensional images. This allows
‘visualisation’ of the mucosa to a depth of 1–2 mm.
Currently performed with a probe through the
working channel of an endoscope, the future may
involve tethered capsule technology and rapid assess-
ment of the tubular oesophagus.44 None of these
technologies have yet achieved the aim of replacing
random biopsies.
Frequency of surveillance
The BSG guidelines have usefully stratified patients
into different risk profiles and suggest altering the fre-
quency of surveillance based on these. Patients with
short-segment BE without IM should be discharged
after two endoscopies but if IM is present, then 3–5
yearly endoscopy is sufficient. If the segment is more
than 3 cm long, 2–3 yearly surveillance is recom-
mended. Implementation within endoscopy units
should focus surveillance more appropriately to those
at higher risk. This is likely to lead to significant cost
savings.45 Once either low-grade dysplasia (LGD) or
HGD is diagnosed and confirmed by two independent
gastrointestinal (GI) pathologists, the BSG now recom-
mends endoscopic treatment as first line and patients
should be referred to a specialist multidisciplinary
team (MDT) for therapy.46 If it is not confirmed,
more intensive surveillance is wise until it becomes
clear that the original histopathological diagnosis was
overcalled, which happens not infrequently.
Diagnosing dysplasia
Perhaps one of the most important issues when con-
sidering monitoring patients is the quality of the histo-
pathological diagnosis. We still rely on entirely
subjective assessment, which is widely recognised as
being flawed. Correlation between pathologists, par-
ticularly for LGD, is poor47 and, until a more reliable
tool is developed and validated, assessment should
ideally be undertaken by two specialist GI patholo-
gists. Approaches that have been tried include p53
immunohistochemistry, which seems to help improve
patient stratification.48 Novel biomarkers and bio-
marker panels continue to be described. A panel of
markers including aneuploidy, a lectin marker and
presence of LGD significantly increased the OR for
cancer.49 Recently, absence of SOX2 expression has
been reported as a highly specific marker of neoplastic
progression.50 This area needs more work.
Treating dysplasia
THE UK RFA Registry has given us useful medium-
term data regarding success of endoscopic resection of
visible lesions followed by radiofrequency ablation for
dysplasia. Reliable data now exist for 5-year outcomes,
with more than 1500 patients in follow-up nationally.
This resource continues to yield new insights. Around
90% of patients will be cured of dysplasia and
Barrett’s mucosa.22 We are getting better at doing this
treatment with time51 and the outcomes are similar
whether the patient has dysplasia or intramucosal
cancer at the time therapy is started.23
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Oesophagectomy, once the gold standard, is now
reserved for the small number who fail first-line treat-
ment and can be a very valuable adjunct therapy.
Monitoring after therapy
Our national registry shows that recurrence of dyspla-
sia does occur after treatment, but it is unusual and
generally occurs soon after treatment is completed.21
Furthermore, the 5-year cancer risk appears to be no
more than 11% at 5 years,51 an 80% reduction com-
pared with historical series. The optimum long-term
follow-up protocol has not yet been definitively estab-
lished, although an international consortium recom-
mended intense surveillance for the first 2 years
followed by annual endoscopies for long term there-
after.34 As our knowledge increases, this schedule is
likely to become more relaxed. Recurrent dysplasia at
the GOJ is now well recognised and biopsies taken at
follow-up endoscopies should always include the
GOJ.52
HEALTH ECONOMICS
The cost-effectiveness of endoscopic screening and
surveillance remains controversial with estimates
ranging between $10 000 and $100 000 per QALY.
Cheaper ways of detecting cancer risk in these
patients are clearly needed.
NEW WAYS OF MONITORING
Let’s move surveillance to the outpatient department
It would be so much easier and cheaper if endoscopy
could be offered during a routine outpatient appoint-
ment, much as ENT surgeons offer nasendoscopy.
Ultra-thin nasal endoscopes now exist and appear to
be able to detect BE reasonably accurately.53 54 The
issues of scope reprocessing may also have been over-
come with a disposable over-sheath.55
Cytosponge
A capsule-on-a-string cytology collection device devel-
oped in Cambridge (the Cytosponge), coupled with
an immuno-based assay, has a high sensitivity for
detecting BE without endoscopy. It is also acceptable
to patients.56 With a sensitivity of almost 90% and a
specificity of 92.4%, it has an accuracy similar to
other screening tests, which opens the way for
population-wide screening.57 58 This may completely
revolutionise the management of patients with BE as
it could move detection from the hospital environ-
ment into the general practitioner (GP) surgery.
Liquid biopsy
Finally, it is interesting to speculate on whether we
can even go one step further.
The concept of ‘liquid biopsy’ is appealing,59
although blood tests are still minimally invasive. Saliva
is easily available and collection can be completely
non-invasive. The genomics revolution is now taking
hold and transcriptomics, the analysis of RNA, is a
dynamic and emerging field. It provides rich informa-
tion on phenotypic changes. Extracellular RNAs
(exRNAs) in human body fluids are emerging as
effective biomarkers for detection of diseases.60 Saliva
has already been shown to harbour exRNA biomar-
kers for several human diseases such as cardiovascular
disease, renal disease, diabetes, infections and
cancer.61–63 Salivary transcriptomics is attractive
because access is entirely non-invasive, the profile is
likely to change over time and significant amounts of
RNA are found in the saliva. It is thought that many
of these RNAs are derived from exosomes, small vesi-
cles that are shed from all cells that make their way
into all body fluids.60 62 Exosomes contain various
molecular constituents of their cell of origin, including
proteins and RNA. There is also early evidence that it
could work. A set of only four salivary transcriptomic
signatures have already been used to identify patients
with resectable pancreatic cancer with an accuracy of
97% for cancer detection.64 In oral cancer detection,
seven mRNA markers led to an accuracy of 74%–
86%.65 Similar work in oesophageal cancer has so far
only yielded accuracies of around 75%,66 but this is
likely to improve with more work. Perhaps endoscopic
monitoring of cancer risk will disappear within a
decade to be replaced by a capsule on a string, or a
small sample of spit in a sputum pot.
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